Combination therapy for advanced nasopharyngeal cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests two different chemotherapy combinations, each given with two extra drugs (one that targets cancer cells and one that boosts your immune system). It's for people with advanced nasopharyngeal cancer who haven't been treated yet, and it aims to see which combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have advanced nasopharyngeal cancer (stage III or IVA).
- You need to be in good overall health (able to do daily activities).
- Your heart, liver, kidneys, and blood counts must be good enough for treatment.
- You haven’t had radiation, chemotherapy, or surgery for this cancer before (except a biopsy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
This trial tests a new combination of drugs and radiation for advanced nasopharyngeal cancer. It aims to improve outcomes by adding a type of immunotherapy and an omega-3 supplement to standard treatment.
This trial tests a new combination of an immunotherapy drug (tislelizumab) plus standard chemoradiotherapy for people with advanced nasopharyngeal carcinoma. It aims to find out if this combination is more effective than standard care alone.
This trial tests a combination of three drugs—an immunotherapy (sintilimab), a targeted therapy (bevacizumab), and chemotherapy—for patients with high-risk, locally advanced nasopharyngeal cancer that has not spread to distant organs. The goal is to see if adding these drugs to standard chemoradiation improves outcomes.
This trial tests a new drug combination called GNT given before standard chemoradiation for people with locally advanced nasopharyngeal cancer. It aims to improve treatment outcomes.
Hear when a new High Risk Locally Advanced Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.